42.975  0.005 (0.01%)		06-21 15:59
Open: 42.97 High: 42.98 Volume: 147,064		Pre. Close: 42.97 Low: 42.94 Market Cap: 1,615(M)

Short term
Mid term
Targets	6-month :	50.25	1-year :	58.7
Resists	First :	43.02	Second :	50.25
Pivot price	42.8
Supports	First :	42.47	Second :	42.13
MAs	MA(5) :	42.85	MA(20) :	42.76
	MA(100) :	42.36	MA(250) :	39.64
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	88	D(3) :	86.2
RSI	RSI(14): 64.9
52-week	High :	45.75	Low :	32.66

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ TARO ] has closed It is unclear right now based on current values. 62.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	42.98 - 43.13	43.13 - 43.27
Low:	42.5 - 42.7	42.7 - 42.88
Close:	42.67 - 42.94	42.94 - 43.19

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Fri, 26 Dec 2025
Sun Pharma’s Taro Recalls 17,000+ Antifungal Shampoo Units in the US - SFC Today

Fri, 26 Dec 2025
Sun Pharma unit Taro recalls over 17k units of antifungal medication in US - Medical Dialogues

Fri, 26 Dec 2025
Sun Pharma’s Taro Recalls Over 17,000 Units of Antifungal Shampoo in US: FDA - NewsGram

Thu, 25 Dec 2025
Panacea Biotec Enhances UNICEF Vaccine Supply Contract; Taro Pharma Recalls Antifungal Medication - scanx.trade

Thu, 25 Dec 2025
Sun Pharma Unit Taro Recalls Antifungal Product in US - Legal Parivar

Thu, 25 Dec 2025
Sun Pharma's Taro recalls over 17,000 units of antifungal shampoo in US amid safety concerns | India News - Hindustan Times

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	38 (M)
Shares Float	8 (M)
Held by Insiders	78.4 (%)
Held by Institutions	13 (%)
Shares Short	74 (K)
Shares Short P.Month	47 (K)

EPS	1.42
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	47.7
Profit Margin	8.5 %
Operating Margin	5.9 %
Return on Assets (ttm)	0.2 %
Return on Equity (ttm)	3 %
Qtrly Rev. Growth	12.5 %
Gross Profit (p.s.)	0
Sales Per Share	16.74
EBITDA (p.s.)	1.02
Qtrly Earnings Growth	118 %
Operating Cash Flow	125 (M)
Levered Free Cash Flow	21 (M)

PE Ratio	30.05
PEG Ratio	0
Price to Book value	0.9
Price to Sales	2.56
Price to Cash Flow	12.96

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.